– CANADA, Vancouver – Mydecine Innovations Group (CSE: MYCO | OTC: MYCOF | FSE: 0NFA) today announced the appointment of Josephine Wu, Founder, and CIO at Aionious Management, to its Board of Directors, replacing Michael Connolly from the Board of Directors.
Mydecine Innovations Group is an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use.
“The Board of Directors welcomes Ms. Josephine Wu to our board as a contributing member as Mydecine continues its growth trajectory. Josephine’s operational and financial leadership in the healthcare and biopharma spaces in addition to her experience bringing numerous successful drugs to market underpins Mydecine’s core strategy in the sector. Her knowledge will be incredibly valuable as we continue to execute on our business model and provide tremendous value to our partners, investors and shareholders.” said Chairman and CEO, Josh Bartch.
The Company would like to thank Mr. Connolly for his time, services, and for the valuable contributions, he made during his tenure as Director.
About Josephine Wu
Josephine Wu has over 18 years of hedge fund, family office, and global asset management experience including 10 years of listed, pre-IPO and early-stage Pan-Asia healthcare investment experience. She has been CIO and portfolio manager with combined assets under management of over US$5 billion. She is the founder and CIO of Aionious Management Limited, a dedicated healthcare investment company which invests and provides business development and commercialization strategies in the pan Asia region, specifically in China. Ms. Wu brings in an extensive network of experts in operation, clinical, market positioning, and regulatory knowledge in the Pan Asia healthcare landscape. Her investments in different stages healthcare companies have led to a few successful commercialization launches of pharmaceutical products, regulatory approvals for decontamination solutions for hospitals and research centers, and the signing of strategic partnerships in commercialization transactions and IPOs.
“I am pleased to join Mydecine’s Board of Directors to support management efforts to develop innovative solutions using psychedelic-assisted therapies to treat the global mental health challenge,” said Josephine Wu. “Throughout my career, I have leveraged my experiences in healthcare to advance both start-up and mature companies through their various stages of development. I am excited to get to assist Mydecine as it continues to progress its business model.”
About Mydecine Innovations Group
Mydecine Innovations Group is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare medicinal mushrooms.
At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best-accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also completed multiple acquisitions since its inception.
For more information: https://www.mydecine.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
